Shares of Orthofix Medical Inc. (NASDAQ: OFIX) are soaring 5.67% in pre-market trading on Tuesday, following the release of the company's impressive third-quarter financial results. The medical device maker reported better-than-expected sales and adjusted EBITDA, demonstrating strong performance across its product lines.

Orthofix's Q3 net sales reached $205.6 million, a 5% year-over-year increase, surpassing the analyst consensus estimate of $200 million. The company's adjusted EBITDA for the quarter came in at $24.6 million, significantly beating the IBES estimate of $20.1 million and representing a robust 28.2% year-over-year growth. The strong performance was driven by several factors, including an 8% growth in U.S. Spine Fixation net sales, boosted by the 7D FLASH™ navigation technology, and a 19% increase in U.S. Orthopedics net sales, supported by the launch of TrueLok™ Elevate.

In light of these positive results, Orthofix has narrowed its full-year 2025 net sales guidance to $810 million-$814 million and raised the low end of its adjusted EBITDA guidance to $84 million-$86 million. The company also expects to generate positive free cash flow for the year, excluding M6 restructuring charges. With a gross margin of 72.2% for the quarter and a positive outlook, investors are showing renewed confidence in Orthofix's growth trajectory, driving the stock's pre-market surge.